Selecta Biosciences' Cash, Cash Equivalents, Restricted Cash, And Marketable Securities Of $115M Is Expected To Fund Operations Into 2027
Portfolio Pulse from Benzinga Newsdesk
Selecta Biosciences has announced that its cash, cash equivalents, restricted cash, and marketable securities total $115M, which is expected to fund its operations into 2027.
August 17, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Selecta Biosciences' financial position is strong with $115M in cash and securities, which is expected to fund its operations until 2027.
The news directly pertains to Selecta Biosciences' financial position. The company's strong cash and securities position, which is expected to fund operations until 2027, is a positive signal for investors. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100